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Accepted 6 August 2017Aim: To report a retrospective, 15-years single-center experience about Carotid Artery Stenting (CAS) using the
Carotid Wallstent in high surgical risk patients.
Methods: Primary outcomes were procedural success, 30-day mortality and cerebrovascular complications, and
long-term survival, neurological complication and restenosis. P values b 0.05 were considered signiﬁcant.
Results: From January 2000 to June 2015, 560 patients underwent CAS using the Carotid Wallstent for either a
symptomatic (22.6%) or an asymptomatic signiﬁcant carotid stenosis. Primary success was achieved in 99.1%
as 4 acute stent thrombosis occurred and in 1 case selective catheterization of the supra-aortic trunks was not
possible due to extreme tortuosity. At 30 days, 7 TIAs and 9 strokes accounted for a 2.8% of neurological compli-
cation rate. There were 2 deaths unrelated to the procedure.
At 10 years, survival was 71.2% ± 2.5%. Freedom from cerebrovascular events (TIA/stroke) at 10 years was
91.2% ± 1.9% for asymptomatic patients and 81.7%± 5% for symptomatic patients (P=0.008). Freedom from a
restenosis N30% was estimated to be of 93.9% ± 1.3% at 10 years, being signiﬁcantly affected by age (P= 0.01).
Conclusion: In our experience the Carotid Wallstent was a safe and effective device for the treatment of both
asymptomatic and symptomatic carotid stenosis in high surgical risk patients. Freedom from cerebrovascular
events in the long term was worse in symptomatic patients.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Carotid artery stenting
Carotid Wallstent
Long-term results1. Introduction
Since the introduction of endovascular therapy as an alternative to
the gold standard carotid endarterectomy (CEA), management of criti-
cal carotid artery stenosis has been one of the most discussed topic in
the literature, as lot of paperswere published aiming to assess the supe-
riority of one method over the other [1].
According tomost trials up to know CEA is still the gold standard for
the treatment of both symptomatic and asymptomatic carotid stenosis
[2].
Thanks to the development of new devices and the improvement of
the techniques, the number of endovascular procedures performed has
increased over time, with a spread of the inclusion criteria. The use ofansient Ischemic Attack; CEA,
ngiography; CTA, Computed
can; EPD, Embolic protection
artery; AUC, Are Under Curve;
D, Cerebral protection device.
rch, preparation andproduction
l.
y, IRCCS Policlinico San Donato,
ro).
. This is an open access article underthe stent instead of a simple balloon dilation, in fact, has allowed the
achievement of excellent immediate and long-term results with a re-
duction of neurological perioperative complication, as the metallic
frame of the stent with the coverage of the plaque usually offers a
good protection from distal embolization.
Self-expandable stents are the choice for the carotid district, because
they present a lower risk of deformation or breakage than the balloon-
expandable stents, in case of sudden movements or neck injury.
Themost used stent is the CarotidWallstent™Monorail™ (Boston),
which is a closed-cells stent with a woven mesh of ﬁlaments in alloy,
characterized by the presence of a greater radial strength than the
other types of stents and the peculiarity to provide a greater coverage
of the plaque.
Aim of the study was to report a retrospective, single-center experi-
ence about Carotid Artery Stenting (CAS) using the Carotid Wallstent
over 15 years in high surgical risk patients.
2. Methods
The study was approved by the Institutional Review Board.
Data of all patients who were treated for a severe carotid stenosis
using the CarotidWallstent from January 2000 to June 2015were retro-
spectively reviewed.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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date of birth, telephone number), medical history (the presence of car-
diovascular risk factors: diabetes mellitus, hypertension, dyslipidemia,
chronic renal failure, ischemic heart disease, smoking, familiar history
of cardiovascular disease, obesity, any previous stroke), preoperative
neurologic symptomswithin the previous sixmonths, side of the lesion,
lesion location, etiology of the lesion (primary stenosis/post-surgical re-
stenosis/in-stent restenosis), degree of carotid stenosis and any contra-
lateral carotid occlusion. Intraoperative data included the use of any
cerebral protection device, pre- and post-dilatation, operation time,
the amount of contrast used, procedural success (deﬁned as a residual
stenosis b 30% [3]), the occurrence of cerebral ischemic events and in-
traoperative complications. The discharge date (length of in-hospital
stay) was also recorded.
Primary outcomes were procedural success (deﬁned as the correct
delivery and placement of the stent without any immediate stent
thrombosis), 30-day mortality and cerebrovascular complications, and
long-term survival, neurological complication and restenosis.
Follow-up data were obtained from reports of outpatient visits and
through telephonic interview (occurrence of cerebrovascular events,
death and any complications). Imaging was performed every 3 months
during the ﬁrst year after the operation and annually thereafter using du-
plex scans to record the occurrence of either restenosis or stent occlusion.
2.1. Patients' selection
In our Operative Unit CEA is still the gold standard treatment for sig-
niﬁcant carotid artery stenosis in low surgical risk patients. CAS is usu-
ally proposed as an alternative to CEA if the patient is a poor surgical
candidate for high risk but with a life expectancy longer than 3 years,
and in absence of any contraindication to CAS such as severe tortuosity
or calciﬁcation of the aortic arch or the supra-aortic vessels, hemorrhag-
ic carotid plaques, or in case of any contraindications to platelet
antiaggregants.
Almost all patients undergo an additional preoperative Magnetic
Resonance Angiography (MRA) or Computed Tomographic Angiogra-
phy (CTA) of the supra-aortic trunks and the intracranial vessels, in
order to have a proper pre-procedural planning for either CAS or CEA,
for the evaluation of the level of carotid bifurcation, the localization
and extension of the stenosis, the presence of any tandem lesions, as
well as for the aortic arch morphology. During the ﬁrst years of our ex-
perience, however, therewas a trend to performduplex ultrasound scan
(DUS) only.
All symptomatic patients usually undergo a preoperative evaluation
by expert neurologists.
A careful preoperative DUS evaluation is performed in all patients on
admission, to assess carotid plaquemorphology, length of the lesion and
diameter of both the common carotid and internal carotid arteries, in
order to optimize a proper choice of the type and measures of the
stent which will be used.
Usually the Carotid Wallstent is chosen in case of “soft” plaques
which need to be covered as much as possible.
Femoral arteries are evaluated as well using duplex scan, to assess
the presence of any iliac-femoral stenosis or plaque in order to choose
the best access for the arterial puncture.
2.2. Implantation technique
All procedures are performed in the operating suite, with
anesthesiological assistance. Cardiac rhythm is routinely monitored, as
well as invasive radial arterial pressure.
Aspirin (100 mg daily) and Clopidogrel (75 mg daily) orally are
started at least 5 days before the endovascular procedure, and contin-
ued for one month after revascularization, then aspirin alone (100 mg
daily) is continued indeﬁnitely. All patients who undergo CAS are
awake during the procedure.A percutaneous femoral access is usually preferred with a short 8 F
sheath. Selective catheterization of the target common carotid artery
is usually performed using two coaxial catheters (a 5.2 F Multipurpose
inside a 8 F 40° guiding catheter). Supra-aortic vessels arising from a
type II or a type III aortic arches, or even from bovine arches, may be se-
lectively catheterized using a Hockey Stick catheter.
Primary stenting is performed whenever possible, using embolic
protection devices (EPDs). In the ﬁrst year of our experience EPDs
weren't routinely used, then they were employed whenever possible.
Post-dilatation is usually achieved using 4.5–6.0 × 20 mm balloons;
intravenous atropine is selectively administered if patients experience
bradycardia (a decrease in heart rate b 50% or an absolute heart rate
of b40 bpm) or hypotension (systolic blood pressure b 90 mmHg) be-
fore insufﬂation of the balloon or before delivering the stent [4]. As for
the access site, manual compression on the arterial access is preferred
in case of a severely diseased femoral artery, otherwise a vascular clo-
sure device (e.g. AngioSeal®) is employed.
2.3. Statistical analysis
Statistical analysis was performed using JMP® 5.1.2 (SAS Institute,
Inc., Cary, NC, USA). Continuous variables are reported as median and
interquartile range (IQR); categorical variables are presented as n (%).
Logistic regression using the Wald statistic was performed to identify
predictors of death or neurological complications. P values b 0.05 were
considered statistically signiﬁcant.
3. Results
Five-hundred and sixty patients underwent CAS using the Carotid
Wallstent for a signiﬁcant carotid artery stenosis (median stenosis de-
gree 80% according to ECST measurement [9]). Their median age was
74 years (IQR 69–79 years) and 71.1% of them were male.
As described in Table 1, the most common patient comorbidities in-
cluded current or previous smoking (63.2%), hypertension (71.6%), and
dyslipidemia (47.5%). No patient presented with severe renal failure.
In 22.6% of cases, the patient had been symptomatic for a cerebro-
vascular event within the previous six months.
Most patients were treated for a primitive carotid artery stenosis. In
6 patients, the CASwas a rescue procedure after CEA, either after a failed
attempt with an important neurological suffering during the carotid
clamping (2 cases) or for a residual distal dissection causing neurologi-
cal impairment (4 cases).
3.1. Procedural data
Primary success was achieved in 555 out of 560 cases (99.1%). Four
patients required an immediate surgical carotid exploration for an
acute stent thrombosis, which was resolved by stent explantation, ca-
rotid endarterectomy and carotid patch angioplasty. In the last case, se-
lective catheterization of the common carotid artery (CCA) was not
possible for extreme vessel tortuosity in a bovine type III aortic arch
and the patient eventually refused any treatment.
Embolic protection devices were used whenever possible (91.25%).
As described in Table 2, a distal ﬁlter was the type of EPDmost used. Pri-
mary stenting was performed whenever possible (95.3%) and pre-dila-
tion of the lesion was reserved only for cases of failed attempt of
primary stenting due to severe stenosis which precluded the delivery
of the stent throughout the lesion. A pre-dilation with cutting-balloon
was performed in one case only because of a severe in-stent restenosis.
In 12 patients, onemore stent was required for the optimal coverage
of the plaque (additional CarotidWallstent and Cordis Precise in 2 and 9
cases respectively). Another patient required the placement of two
more stents (both of them Cordis Precise).
Post-dilation was performed in 95.9% of patients, and in most cases
one dilation was enough to achieve an optimal result.
Table 1
Patients' characteristics and anatomical data.
n = 560
Male sex 398 (71.1%)
Median age, years (IQR) 74 (69–79)
Comorbidities
Current or previous smoke 354 (63.2%)
Coronary artery disease 202 (36.1%)
Hypertension 401 (71.6%)
Dyslipidemia 266 (47.5%)
Diabetes 128 (22.8%)
Obesity 73 (13%)
Chronic Renal Failure 75 (13.4%)
Familiar history of cardiovascular disease 141 (25.2%)
Preoperative symptoms 127 (22.6%)
Any previous stroke (before 6 months) 29 (5.2%)
Anatomical data (median, IQR)
Degree of stenosis (ECST method) 80% (75% - 85%)
Side of the lesion
Left 278 (49.6%)
Right 282 (50.4%)
Tandem lesion 91 (16.2%)
Location
Carotid bifurcation 546 (97.5%)
CCA 14 (2.5%)
Etiology of the stenosis
Atherosclerotic lesion 458 (81.7%)
Post-radiation stenosis 21 (3.7%)
In-stent restenosis 7 (1.2%)
Post-CEA restenosis 74 (13.3%)
Rescue of CEA procedures 6 (1.1%)
Contralateral carotid artery
Mild stenosis 30 (5.4%)
Severe stenosis 30 (5.4%)
Occluded 87 (15.6%)
Previous CEA/CAS 93 (16.6%)
Tortuosity of carotid vessels/aortic arch
Severe tortuosity 39 (6.9%)
Mild tortuosity 240 (42.8%)
Absence of tortuosity 281 (50.2%)
Features of the carotid plaque
Ulcerated 22 (3.9%)
Fibrolipidic 259 (46.3%)
Calciﬁed 279 (49.8%)
CCA = Common Carotid Artery.
CEA = Carotid Endarterectomy.
CAS = Carotid Artery Stenting
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pseudoaneurysm (0.7%) that was manually compressed with complete
exclusion in all but one case, and three had a superﬁcial groin hemato-
ma (0.5%) which didn't require any blood transfusion nor surgical evac-
uation and resolved spontaneously. One patient had a pneumonia andTable 2
Intraprocedural and in-hospital data (Median, IQR).
n = 560
Procedural successa 555 (99.1%)
Embolic Protection Device
FilterWire EZ 473 (84.5%)
Emboshield/Neuroshield 25 (4.5%)
PAEC 6 (1%)
MoMa 2 (0.35%)
Angioguard 5 (0.9%)
Vascular Access Closure
Manual compression 505 (90.2%)
Endovascular closure device 55 (9.8%)
Time of operation (min) 40 (30–50)
Amount of contrast (cc) 75 (70–85)
Fluoroscopy time (min) 15 (9–18)
Length of stay (days) 2 (2–3)
a Four acute stent thrombosis which required immediate surgical explora-
tion and 1 failed attempt of selective catheterization of the CCA.another patient developed an allergic reaction to contrast medium
which was previously unknown. The patient had intraoperative skin
rashwhichwas resolved immediately after administration of corticoste-
roids and antihistamines drugs.
Two deaths occurred within 30 days (0.3%): 1 for traumatic causes
and one for a cardiac arrhythmia (Table 3). In seven symptomatic pa-
tients an ipsilateral minor stroke occurred within 30 days, one of them
during in-hospital stay (Table 3). All of these patients however gradual-
ly recovered and became clinically asymptomatic within 6months. Two
contralateral major strokes were observed in 18th and 11th postopera-
tive day respectively, in patients whowere neurologically asymptomat-
ic before the procedure. Seven patients (1.2%) experienced a Transient
Ischemic Attack (TIA) within 30 days, one of them immediately at the
end of the procedure. In all of these cases, symptoms completely disap-
peared within 24 h and the computed tomography of the brain was
negative.
3.2. Long-term follow-up data
The median follow-up period was 78.2 months (IQR 37–
121.5 months).
3.2.1. Survival
Survival at 1, 5 and 10 years was 96.6% ± 0.7%, 86.2% ± 1.6% and
71.2%±2.5% respectively (Fig. 1), without any signiﬁcant difference be-
tween neurologically symptomatic and asymptomatic patients.
Age was a signiﬁcant factor affecting long-term survival (P= 0.01),
in particular for patients aged 71 andmore at the time of the procedure
(AUC 0.54, R2 = 0.0065).
Contingency analysis of factors which signiﬁcantly affected long-
term survival showed that male sex, preoperative neurological symp-
toms and the occurrence of stroke within 30-days were independently
associated with death (P = 0.04, 0.04 and 0.001 respectively, see
Table 4).
Also procedures which lasted for N40min were signiﬁcantly related
to the occurrence of death in the long-term (P = 0.0017, R2 = 0.01;
Area Under Curve= 0.61 at Receiver Operating Characteristic analysis).
Neoplasm was the main cause of death, followed by cardiologic and
neurodegenerative diseases. Traumatic events also accounted for an im-
portant number of deaths in the long-term.
3.2.2. Cerebrovascular events
The occurrence of cerebrovascular events (TIA/stroke) in the long-
term was signiﬁcantly different between asymptomatic and symptom-
atic patients, being worse for the latter (P= 0.008).
Particularly, freedom from any cerebrovascular event at 1, 5 and
10 years was 98.6%± 0.6%, 97.1%± 0.8% and 91.2%± 1.9% respectively
for asymptomatic patients, and 96.8%± 1.6%, 95.7%± 1.9% and 81.7%±
5% respectively for symptomatic patients (Fig. 2).
The use of any EPDwas signiﬁcantly related to a lower occurrence of
either TIA or stroke in the long term (P= 0.009).
On the other side, patients who had experienced a TIA within the
ﬁrst 30 postoperative days were more likely to be affected by either a
recurrence of TIA or a major event in the long term (P b 0.0001, see
Table 4).Table 3
Thirty-day results.
n = 560
Death 2 (0.3%)
Myocardial Infarction 2 (0.3%)
Any stroke 9 (1.6%)
TIAa 7 (1.2%)
a Transient Ischemic Attack.
Fig. 1. Long-term survival.
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rence of cerebrovascular events in the long term, as this complication
was more likely to occur in patients in whom the procedure had
been performed by an operator in the ﬁrst phase of his learning curve
(P= 0.01).Table 4
Pearson's correlation for factors signiﬁcantly associated with the occurrence of death and
stroke in the long-term (P values).
Death Stroke
Male sex 0.04 0.83
Age 0.01 0.55
Preoperative symptoms 0.04 0.0066
CAD 0.23 0.62
DM 0.09 0.4
Hypertension 0.17 0.89
Dyslipidemia 0.36 1
CRF 0.09 0.86
Previous stroke 0.77 0.15
Duration of procedure 0.0017 0.09
First Operator 0.06 0.01
Contralateral carotid occlusion 0.3 0.2
EPD 0.13 0.009
Ulcerated plaque 0.09 0.2
Predilation 0.4 0.91
Stroke within 30 days 0.001 0.94
TIA within 30 days 0.62 b0.0001
Immediate stent thrombosis 0.17 0.44
MI within 30 days 0.31 0.59
Signiﬁcant P value in bold.
CAD = Coronary Artery Disease.
DM= Diabetes Mellitus.
CRF = Chronic Renal Failure.
TIA = Transient Ischemic Attack.
MI = Myocardial infarction.
EPD = Embolic Protection Device.The type of carotid plaque was not related to the occurrence of any
cerebrovascular event in the long-term, neither the presence of a tortu-
osity of the supra-aortic vessels.
3.2.3. Restenosis
Freedom from a restenosis N30% detected at ultrasound examina-
tion was estimated to be of 99.16% ± 0.4%, 96.01% ± 0.9% and 93.9%
± 1.3% respectively at 1, 5 and 10 years (Fig. 3), however a signiﬁcant
in-stent restenosis N80% [5] was detected only in 7 patients, one of
whomhad experienced the occurrence of a TIA. Inmost cases, the reste-
nosis was corrected using a simple balloon dilation (5 patients). A cut-
ting balloon was used in one patient who had a severe in-stent
restenosis due to a huge ﬁbromuscular hyperplasia. In the remaining
patient, another Carotid Wallstent was deployed inside the previous
one, which presented a severe recoil in its middle third due to a highly
calciﬁed external plaque.
Contingency analysis showed that agewas the only factorwhich sig-
niﬁcantly affected the occurrence of restenosis in the long-term (P =
0.01, see Table 5), in particular for patients aged 72 years and more
(R2 = 0.02; Area Under Curve = 0.65 at Receiver Operating Character-
istic analysis).
4. Discussion
Endovascular management of critical carotid artery stenosis has
been one of the most discussed topic in the literature since the last ten
years, as many papers were published in the scientiﬁc literature com-
paring CEA to Carotid Artery Stenting (CAS) with the aim to assess the
superiority of one method over the other [2].
Thanks to the use of the stent instead of a simple balloon dilation, the
procedure has achieved excellent immediate and long-term results
with a reduction of neurological perioperative complication, as the me-
tallic frame of the stent with the coverage of the plaque usually offers a
good protection from distal embolization. Moreover in our experience
Fig. 2. Long-term estimated freedom from stroke.
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from an initial strategy of predilation which could generate distal
emboli.
The plaquemorphology plays an important role in the occurrence of
postoperative cerebral ischemic events. Particularly, Brott and Coll.
demonstrated that «plaque instability» determined procedural risk in
CREST [6].
In the light of these assumptions, it is crucial to use a stent with a
morphology that ensures an excellent navigability through the lesion
and the smallest “maximum unprotected circular area”, which is index
of plaque prolapse towards the lumen.
For the treatment of carotid stenosis, self-expandable stents repre-
sent the best choice, because they carry a lower risk of deformation orFig. 3. Long-term estimated fbreakage than the balloon-expandable stents, in case of sudden move-
ments or neck injury. The most used stent is the Carotid Wallstent
(Boston).
More recently the self-expandable nitinol stents (Precise, Cordis;
ACCULINK, Guidant; X-act, MedNova; etc.) have been introduced.
They are characterized by a greater radial strength and a greater adapt-
ability to vessel tortuosity and to differences between the size of the in-
ternal and the common carotid artery.
The choice of the more appropriate stent depends on the ease of
placement with the least risk of acute complications.
Bosiers and Coll. in the ELOCAS study [7] reported data about 2172
patients who underwent CAS in 4 high-volume European centers. In
1261 of them, the Carotid Wallstent was the choice, with a 3-yearreedom from restenosis.
Table 5
Pearson's correlation for factors signiﬁcantly associated with the occurrence
of restenosis in the long-term (P values).
Restenosis
Male sex 0.7
Age 0.01
Preoperative symptoms 0.77
CAD 0.09
DM 0.84
Hypertension 0.97
Dyslipidemia 0.15
CRF 0.11
Previous stroke 0.69
Duration of procedure 0.97
First Operator 0.14
Contralateral carotid occlusion 0.16
EPD 0.77
Ulcerated plaque 0.15
Predilation 0.11
Stroke within 30 days 0.51
TIA within 30 days 0.54
Immediate stent thrombosis 0.64
MI within 30 days 0.74
Signiﬁcant P value in bold.
CAD = Coronary Artery Disease.
DM= Diabetes Mellitus.
CRF = Chronic Renal Failure.
TIA = Transient Ischemic Attack.
MI = Myocardial infarction.
EPD = Embolic Protection Device.
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hort, which compared favourably to the 3-year outcome of CEA in
symptomatic patients.
The CABANA study [8] in 2012 was designed to speciﬁcally evaluate
CAS results in high-surgical-risk patients treated with the Carotid
Wallstent by a broad-based group of providers. In this prospective, sin-
gle-arm study,White and Coll. will analyze 30-day stroke, death, andMI
rates after 1097 CAS performed at 99 study centers whichmeet the cre-
dential-based training requirements for participating in the study itself.
In their evaluation [9], the Authors found a 30-day stroke rate of 3.3%,
which was a major contributing factor in the overall major adverse
events rate (MAE, 4.6%). Mortality was 1.3% and the MI rate was 0.5%.
They did not found either statistically signiﬁcant association between
MAE rates among the center experience tiers (P = 0.61) nor among
the operator training categories (P= 0.26).
Moreover, Doig and Coll. [10] recently investigated the effect of
baseline patient demographic factors, processes of care, and technical
factors during CAS on the risk of stroke, myocardial infarction (MI), or
death within 30 days of CAS in the International Carotid Stenting
Study (ICSS). Their results favored the use of closed-cell stents as the
open-cell stent conferred a 1.92 time higher risk of developingperioper-
ative stroke, MI or death. Cerebral protection device (CPD) use did not
modify this risk.
Therefore, according towhat is reported in the literature, the Carotid
Wallstent seems to be a stent that provides good protection especially in
symptomatic patients, someway regardless of the expertise of the indi-
vidual operators.
In our experience the Carotid Wallstent was a safe and effective de-
vice for the treatment of both asymptomatic and symptomatic carotid
stenosis in high surgical risk patients.In particular, it showed a good navigability through almost all type of
anatomies without increasing signiﬁcantly the risk of neurological
adverse events, as no relation was noted between the presence of a tor-
tuosity of the supra-aortic vessels and the occurrence of any cerebrovas-
cular event in the long-term.
As reported in the literature, also in our experience the Carotid
Wallstent offered a good protection towards “soft” plaques, as evi-
denced also by the fact that the type of carotid plaque was not related
to the occurrence of neurological impairment in the long-term.
On the other side, the expertise of the operator played an important
role in the occurrence of cerebrovascular events, nevertheless it was
probably due to a longer manipulation of the catheters in the aortic
arch performed by inexperienced operators rather than to the learning
curve of the Carotid Wallstent.
The strength of our study is represented by the high number of pro-
cedures performed over 15 years in a single Institution. Moreover, in al-
most half of the cases of our series, the CarotidWallstentwas chosen for
the presence of a “soft” plaque, in patients who could not undergo CEA
because of surgical comorbidities.
Limitations of our study are represented by the retrospective nature
of the analysis. It would be interesting to compare the occurrence of 30-
days and long-term cerebrovascular events between patients submitted
to CAS using the Carotid Wallstent and those submitted to CEA during
the same period.Conﬂict of interest
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